23 million shares outstanding, 80% institutionally owned. FDA approved drug for migraines, with unique delivery mechanism for the nostrils. Only have 4 weeks of sales history in Q3 from approval, but it was robust. Q4 results we be pivotal event..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.